Abstract | BACKGROUND: OBJECTIVE: The aim of our study was to determine the efficacy of acitretin (20 to 30 mg/day) for 16 weeks in LSA. METHODS: Seventy-eight patients were enrolled into a multicenter, randomized, placebo-controlled, double-blind trial. The primary measure of efficacy was the "responder" rate based on the assessment of characteristic clinical features of LSA of the vulva ( pruritus, burning, atrophy, hyperkeratosis, and secondary features such as erosions, ulcers, edema, or lichenification) and on the extent of the lesions. RESULTS: From the 46 patients eligible for efficacy analysis, a significantly higher number of responders was observed in the acitretin-treatment group (14 of 22 patients) as compared with the placebo-treatment group (6 of 24 patients). Typical retinoid adverse reactions were observed in all patients receiving active drug. CONCLUSION:
Acitretin is effective in treating women with severe LSA of the vulva.
|
Authors | M T Bousema, U Romppanen, J M Geiger, M Baudin, K Vähä-Eskeli, J Vartiainen, S Vuopala |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 30
Issue 2 Pt 1
Pg. 225-31
(Feb 1994)
ISSN: 0190-9622 [Print] United States |
PMID | 8288782
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Acitretin
(adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Lichenoid Eruptions
(drug therapy)
- Middle Aged
- Vulvar Diseases
(drug therapy)
|